Related Experiment Video
Updated: Jun 27, 2025
07:39
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
81
FYB1-targeted modulation of CAPG promotes AML progression
Wenyuan Liu1, Hongli Yin2, Zhiwei Xie1
1Department of Pediatrics, The Second Affiliated Hospital of Anhui Medical University, No. 678 Furong Road, Hefei City, 230601, Anhui Province, China.
Molecular and Cellular Biochemistry
|May 3, 2024
Summary
High FYB1 expression correlates with poor prognosis in acute myeloid leukemia (AML). Targeting the FYB1/CAPG axis may offer new therapeutic strategies for AML patients.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Acute myeloid leukemia (AML) is a complex blood cancer with limited treatment options for patients with drug resistance or relapse.
- Improving therapeutic strategies and patient prognosis for AML remains a critical unmet need.
Purpose of the Study:
- To investigate the role of FYB1 expression in AML progression and its correlation with patient prognosis.
- To identify and analyze the downstream targets of FYB1, specifically focusing on their impact on AML.
Main Methods:
- Analysis of large patient databases and gene expression data.
- In vivo and in vitro experiments, including FYB1 knockdown and RNA sequencing.
- Investigation of the downstream target gelsolin-like actin-capping protein (CAPG) in AML cells.
Main Results:
- FYB1 expression was significantly elevated in AML tissues and associated with poorer overall survival.
- FYB1 knockdown suppressed AML cell proliferation, induced apoptosis, reduced adhesion, and decreased tumor formation in mice.
- FYB1 knockdown led to decreased CAPG expression, and CAPG suppression inhibited proliferation and increased apoptosis in AML cells.
Conclusions:
- The FYB1/CAPG axis plays a crucial role in promoting AML progression.
- Targeting the FYB1/CAPG axis represents a potential novel therapeutic strategy for acute myeloid leukemia.
Related Concept Videos
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
01:15Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K